SCHEMBL23771663

SCHEMBL23771663

CCCCC(C)(C)C(=O)CCC(C)(C)OCC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
FAAH O00519 8/20 0.33
CES1 P23141 7/20 0.32
CES2 O00748 4/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
CYP1A2 P05177 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
ACAT1 P24752 1/20 0.32
SOAT1 P35610 1/20 0.32
ATM Q13315 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26389556 0.83 CYP4F2 (0.31) CYP4F2CYP4A11
SCHEMBL23771649 0.83 FAAH (0.32) FAAHCES1CES2MEN1KMT2A
SCHEMBL26389354 0.83 ALDH1A1 (0.33) FAAHCES1CES2MEN1KMT2A
SCHEMBL19325218 0.79
SCHEMBL8896813 0.78 FAAH (0.41) FAAHCES1CES2MEN1KMT2A
SCHEMBL6721146 0.76 TSHR (0.32) TSHR
SCHEMBL20844358 0.76 FDPS (0.39) FAAHCES1CES2MEN1KMT2A
SCHEMBL8897721 0.75 FAAH (0.57) FAAHCES1CES2MEN1KMT2A
SCHEMBL19333175 0.73 FAAH (0.38) FAAHCES1CES2MEN1KMT2A
SCHEMBL28184813 0.72 ALDH1A1 (0.42) MEN1KMT2ACYP1A2HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780900-B2 Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof Janssen Sciences Ireland Unlimited Company (IE) 2023-10-10 US disclosed
US-20210253661-A1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF Janssen Sciences Ireland Unlimited Company (IE) 2021-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253661-A1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF GLP1R, GIPR, IAPP CYP4F2 2730/4885CYP4A11 3263/4885FAAH 2948/4885
US-11780900-B2 Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof GLP1R, GIPR, IAPP CYP4F2 2730/4885CYP4A11 3263/4885FAAH 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.